EGFR
-
VUMC scientists discover key step to kidney fibrosis
Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure. Read MoreNov 21, 2023
-
Study supports removing race from estimate of kidney function
An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function. Read MoreNov 17, 2022
-
Study reveals need for matching targeted therapies with EGFR subtypes
A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers. Read MoreJul 28, 2022
-
The role of polarity in early cancer
Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered. Read MoreSep 21, 2021
-
Blocking tumor ‘signals’ and ‘fuel’
Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients. Read MoreAug 25, 2020
-
Protein study may be key to treating fibrotic diseases
A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently. Read MoreJul 30, 2020
-
Sex differences in kidney injury
Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor. Read MoreJul 25, 2019
-
Researchers find novel mechanism of resistance to anti-cancer drugs
Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance. Read MoreOct 17, 2017
-
New tools to combat kidney fibrosis
Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies. Read MoreOct 13, 2017
-
Glowing receptors help find and track cancerous growth
Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth. Read MoreMay 18, 2017
-
New target for colorectal cancer
Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development. Read MoreMar 17, 2017
-
EGF receptor found to regulate macrophage inflammation in gut
Researchers at Vanderbilt University School of Medicine have uncovered a link between epidermal growth factor receptor (EGFR) signaling and the inflammatory response to bacterial infection in the gastrointestinal tract. Read MoreOct 13, 2016
-
Drug combos for glioblastoma
Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment. Read MoreMay 3, 2016
-
Bad “traffic” linked to cancer
Understanding how signaling molecules are transported within and out of the cell may help to uncover the causes of certain cancers. Read MoreSep 3, 2015
-
Probing mutant EGF receptor regulation
Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies. Read MoreOct 10, 2013
-
Plant compound stops colon cancer cells
Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy. Read MoreMar 29, 2013
-
HER2 may impact lung cancer therapy
A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies. Read MoreSep 21, 2012